Up north, in Manchester NH, David Platt, Ph.D., Chairman and Chief Executive Officer of Boston Therapeutics, has been developing an amazing new drug for type 2 diabetics.
He calls it PAZ 320.
Unlike traditional diabetes fighting drugs which target the pancreas or other organs, PAZ 320 works on enzymes specific to diabetes. It actually blocks the enzymes that release glucose into the blood. Other drugs that act on enzymes target only one, where PAZ 320 blocks all of those distinctly related to accomplishing such a goal.
“PAZ 320 has everything to do with type 2 diabetes,” Dr. Platt said.
Dr. Platt designed an entirely new molecule to accomplish such a medical breakthrough.
“This is unlike any other drug on the market,” said Dr. Platt. “If you control the blood glucose, you control the diabetes
In use it is to be taken before a meal which impacts glucose after eating, and it's chewable.
“Also, there are no safety issues whatsoever,” he continued. “It goes in and it comes out…no interruption. It has the highest safety in chemistry.”
PAZ 320 has passed phase two of clinical study. The FDA has given the go-ahead phase three.
In the second phase it was discovered that type 2 diabetics taking Metformin showed the greatest improvement, so the restriction for phase three participants must be taking that medication. They will need 300-500 participants and it will be based out of New Hampshire.
To see if you qualify keep an eye on http://clinicaltrials.gov/ to learn when the study will start.
Doug Atkins’ award winning novel, The Watchers, is available on Amazon